Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026
Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Jan 1, 2025

US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of...

Company Drug

Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer

Fineline Cube Jan 1, 2025

China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...

Company Drug

Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema

Fineline Cube Jan 1, 2025

Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...

Company Drug

Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment

Fineline Cube Jan 1, 2025

US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...

Company Deals

BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074

Fineline Cube Jan 1, 2025

Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...

Company Drug

Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment

Fineline Cube Jan 1, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...

Drug Medical Device Policy / Regulatory

10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion

Fineline Cube Dec 31, 2024

The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...

Company Deals

Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation

Fineline Cube Dec 31, 2024

Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...

Company Drug

Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006

Fineline Cube Dec 31, 2024

China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China

Fineline Cube Dec 31, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT)...

Company Deals

We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 31, 2024

China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...

Company Deals

Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion

Fineline Cube Dec 31, 2024

China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a...

Company Drug

Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer

Fineline Cube Dec 31, 2024

Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...

Company Drug

CanSino Biologics’ Menhycia Receives Market Approval in Indonesia

Fineline Cube Dec 31, 2024

China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors

Fineline Cube Dec 31, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections

Fineline Cube Dec 30, 2024

Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA)...

Company Deals

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849

Fineline Cube Dec 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...

Company Drug

CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study

Fineline Cube Dec 30, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...

Company Drug

argenx’s Vygart Hytrulo Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Dec 30, 2024

Holland-based argenx SE (NASDAQ: ARGX) has announced receiving another indication approval from Japan’s Ministry of...

Company Drug

Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer

Fineline Cube Dec 30, 2024

Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...

Posts pagination

1 … 192 193 194 … 622

Recent updates

  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
  • Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage
  • Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.